Multiple Primary Lung Cancer
Conditions
Keywords
electromagnetic navigation bronchoscopy, microwave ablation, sequential surgery
Brief summary
The goal of this clinical trial is to evaluate the safety and efficacy of ENB guided MWA combined with VATS versus sequential surgery for synchronous bilateral multiple primary lung nodules. Participants will be divided into two group.One group will accepte treatment of ENB guided MWA combined with VATS,another will accepted sequential surgery.
Detailed description
Lung cancer is one of the most common cancers and the leading cause of cancer-related death worldwide. With the improvement of people's health awareness and the wide application of LDCT and HRCT, the incidence of multiple primary lung cancer is increasing, especially the synchronous bilateral multiple primary pulmonary nodules are the difficulties in the treatment of pulmonary nodules. Bilateral sequential surgery is associated with higher intraoperative risks, higher rates of postoperative complications, and lower postoperative quality of life. At present, a small number of recent retrospective studies have shown that microwave ablation(MWA) guided by electromagnetic navigation bronchoscopy(ENB) combined with video-assisted thoracic surgery(VATS) treatment can effectively treat bilateral multiple primary pulmonary nodules, which not only has a low complication rate, but also can avoid secondary surgery. Based on previous studies, the research plans to conduct a prospective, multi-center, randomized controlled study to evaluate the safety and efficacy of ENB guided MWA combined with VATS versus sequential surgery for synchronous bilateral multiple primary lung nodules, as well as its potential value as a new treatment option for these participants.
Interventions
PROCEDUREENB guided MWA combined with VATS
ENB guide MWA combine ENB, microwave ablation and 3D reconstruction technology, and guide the probe in the airway to the target lesion for ablation therapy, which is safe and effective. For patients with synchronous bilateral multiple primary pulmonary nodules, ENB guide MWA combined with VATS treatment can not only avoid the risk of bilateral surgery, but also complete the one-stop treatment, which is a new treatment mode.
PROCEDUREsequential surgery
Bilateral surgery is a traditional treatment, but it will lead to increased intraoperative risk and postoperative complication rate, and more likely to lead to postoperative complications such as decreased quality of life and cardiopulmonary dysfunction.
Sponsors
Sun Yat-sen University
Tang-Du Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Ruijin Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
1. Aged ≥18 years and ≤80 years; 2. The subjects are diagnosed synchronous bilateral multiple primary lung nodules by HRCT 3. The primary nodule is diagnosed as lung cancer by preoperative puncture or multidisciplinary discussion, which can be treated with radical surgery. 4. At least one secondary lesion (6mm≤diameter≤20mm, CTR\<0.5) is contralateral to the primary nodule，which need treatment after multidisciplinary discussion 5. The ipsilateral secondary lesions can be treated by sublobar resection at the same time 6. ECOG PS score 0-1 7. The subjects participate voluntarily and sign a written informed consent;
Exclusion criteria
1. Patients have contraindications of surgery or anesthesia 2. Patients are unable to undergo bronchoscopy 3. A contralateral secondary lesion is unreachable during ENB planning 4. There are large blood vessels 2 mm near the contralateral secondary lesion 5. Patients have severe bleeding tendency and coagulation dysfunction which cannot be improved in a short time 6. Patients have interstitial pneumonia, pulmonary fibrosis, or severe emphysema 7. Patients have diseases,like severe anemia, dehydration, severe nutritional and metabolic disorders, which cannot be cured or improved in a short time 8. Patients have severe systemic infection and fever (\>38.5°C) 9. Patients have other malignant tumors 10. Patients have participated in other clinical trials 11. Investigators consider the patient do not fit for the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total perioperative complication rates | From the time of treatment to one month after operation | Complications refer to operation-related adverse events during and after the operation according to the Clavien-Dindo Classification, including pulmonary infection, Broncho-pulmonary hemorrhage, respiratory failure, pleural effusion, pneumothorax, persistent lung leak, arrhythmia, wound infection, death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate(ORR) | One and three months after ablation | Objective response rate（ORR）is the proportion of patients with complete responses and partial responses. |
| Treatment-related side effects | From the time of treatment to one month after operation | Number of participants with treatment-related adverse events as assessed by CTCAE 5.0. |
| The operation time | During operation | the duration of the operation in minutes. |
| The intraoperative blood loss | During operation | the volume of blood loss in ml. |
| Postoperative hospital stay (days) | One months after treatment | The time of hospitalization in days. |
| Postoperative extubation time (days) | One months after treatment | The duration of chest drainage in days. |
| Mortality within 30 days after surgery | One month after treatment | number of death within 30 days after surgery. |
| The proportion of completed two operations | During operation, an average of 4 months | the patients in control group complete two operations |
| The overall cost of treatment | During hospitalization, an average of 2 weeks | The overall cost of treatment include direct and indirect costs. Additional costs for hospitalization and surgery. |
| Complications (grade ≥3) | One and three months after treatment | complications above grade 3 that need to be treated during and after the operation according to the Clavien-Dindo Classification. |
| Life expectancy(EORTC QLQ-LC29) | One and three months and every year after treatment | patients' quality of life by questionnaires according to EORTC QLQ-LC29. |
| Lung function | One and three months and every year after treatment | forced expiratory volume in one second(FEV1). |
| 3-year disease-free survival(DFS) | A follow-up period of 3 years | DFS : the time from surgical resection to clinically confirmed local recurrence, distant metastasis, second primary tumor diagnosis, or patient death (control group since the second operation). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Biopsy success rate | During operation | The percentage of people with successful biopsy. |
| Biopsy positive rate | During operation | The proportion of patients with malignant biopsies in the overall population |
Countries
China
Contacts
Primary ContactHecheng Li, PhD, MD
Backup ContactDingpei Han, PhD, MD
Outcome results
None listed